Protecting the Health of the Public — Institute of Medicine Recommendations on Drug Safety
Authors:
- Sheila P. BurkeSBSheila P. Burke
- 26 October 2006
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 355 (17) , 1753-1755
Abstract
Soon after rofecoxib had been withdrawn from the market in September 2004, hearings of the Senate Finance Committee and editorials in the lay and medical press raised serious questions about drug safety in the United States. In response, the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA) asked the Institute of Medicine (IOM) to assess the U.S. drug-safety system. The IOM assembled a diverse panel of experts without ostensible bias or conflict of interest, none of whom were pharmaceutical industry employees. The committee, on which we served, reviewed published literature, held open meetings, and received comments from the pharmaceutical industry, the FDA, and nonprofit groups. In September 2006, the IOM released the committee's findings and recommendations.1Keywords
This publication has 2 references indexed in Scilit:
- Blueprint for a Stronger Food and Drug AdministrationNew England Journal of Medicine, 2006
- Lessons from the glitazones: a story of drug developmentThe Lancet, 2001